Why Insulet (PODD) is a Top Growth Stock for the Long-Term

Zacks Investment Research promotes its proprietary Zacks Rank, which has historically delivered a 23.75% average annual return, alongside its complementary A-F graded Style Scores (Value, Growth, Momentum, and VGM) for identifying high-potential stocks. Applying this framework, Insulet (PODD), a medical device company, is highlighted as a compelling growth prospect. Despite a Zacks Rank #3 (Hold), PODD boasts an 'A' for both its Growth Style Score and overall VGM Score, underpinned by a projected 37% year-over-year earnings growth, recent upward revisions from analysts for FY2025 earnings to $4.44/share, and an average earnings surprise of +19.5%. This profile positions PODD as a notable consideration for growth-oriented investors.

Analysis

Insulet Corporation (PODD) presents a compelling growth profile according to the provided metrics, despite a neutral Zacks Rank of #3 (Hold). The company receives top-tier 'A' ratings for both its Growth Style Score and its overall VGM Score, signaling a strong fundamental outlook. This is quantitatively supported by a forecast for 37% year-over-year earnings growth in the current fiscal year and a consistent history of outperformance, reflected in an average earnings surprise of +19.5%. Analyst sentiment appears to be improving, with three upward earnings estimate revisions for fiscal 2025 over the last 60 days, pushing the consensus estimate up by $0.10 to $4.44 per share. The combination of a strong growth forecast, positive analyst revisions, and a track record of beating expectations positions PODD as a notable entity within the medical device sector, even with its current neutral rating.

Key Decisions for Investors

• Investors with a growth-focused mandate should consider PODD's robust 37% forecasted earnings growth and 'A' Growth Score as a strong positive signal, warranting further due diligence.
• The discrepancy between the neutral #3 (Hold) rank and the strong underlying growth metrics suggests investors should monitor for a potential ratings upgrade, which could act as a significant bullish catalyst.
• Given the history of positive earnings surprises and recent upward revisions, investors should closely watch upcoming earnings announcements to see if the trend of beating the $4.44 FY2025 consensus estimate continues, which would validate the ongoing growth narrative.